Abstract 394P
Background
T-DXd is currently approved for the treatment of HER2+ and HER2-low MBC. Immunohistochemistry (IHC) for HER2 does not reliably predict outcomes within these groups. We assessed the performance of a new quantitative test to predict outcomes with T-DXd for MBC.
Methods
We retrieved samples for patients (pts) with MBC receiving T-DXd at DFCI from 7/2017 to 2/2023. The QuPath Qymia method of quantitative immunofluorescence was used to determine HS-HER2. A pathologist circled the region within each biopsy to be measured; then, using a cell line standard curve calibrated by mass spectrometry, the amount of HER2 protein was measured in units of attomols/mmˆ2 in pre-T-DXd samples. We evaluated the association of HS-HER2 in the closest samples collected prior to T-DXd with time to next treatment (TTNT) and overall survival (OS) in continuous terms and by quartiles of HS-HER2.
Results
Samples from 51 pts (32 with HER2+, 19 with HER2- MBC at time of T-DXd) were analyzed with HS-HER2; the primary tumor in 20 pts (39.2%), metastatic biopsy in 13 (25.5%), and both in 18 (35.3%). The median time from tissue collection to T-DXd was 31.3 months (range 2.5 – 204). Across all pts, HS-HER2 was found to be associated with TTNT (hazard ratio [HR] per 5-unit increment 0.78, p75%
Conclusions
The quantitative assessment of HER2 in attomols/mmˆ2 was found to predict clinical outcomes with T-DXd for MBC, including in subgroup analyses for HER2+ and HER2- MBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
P. Tarantino: Financial Interests, Personal, Invited Speaker: AstraZeneca, Roche; Financial Interests, Personal, Advisory Board: Daiichi Sankyo, AstraZeneca, Daiichi Sankyo, Genentech, Eli Lilly, Gilead; Financial Interests, Institutional, Funding: AstraZeneca. L. Alder: Financial Interests, Research Funding, clinical trial funding: BergenBio, ORIC. C. Anders: Financial Interests, Research Funding: PUMA, Lilly, Merck, Seattle Genetics, Nektar, Tesaro, G1-Therapeutics, ZION, Novartis, Pfizer, AstraZeneca, Elucida, Caris, Incyclix; Financial Interests, Speaker, Consultant, Advisor, consulting: Genentech, Eisai, IPSEN, Seattle Genetics, AstraZeneca, Novartis, Immunomedics, Elucida, Athenex, Roche; Financial Interests, Royalties: UpToDate, Jones and Bartlett. S. Morganti: Other, expenses: AstraZeneca, Menarini. A.C. Garrido-Castro: Financial Interests, Personal, Advisory Board: AstraZeneca, Daiichi Sankyo, Novartis; Financial Interests, Personal, Invited Speaker: AstraZeneca, Daiichi Sankyo; Financial Interests, Institutional, Funding, Research funding: AstraZeneca, Daiichi Sankyo, Gilead Sciences, Merck, Zenith Epigenetics, Bristol-Myers Squibb, Novartis, Biovica, Foundation Medicine, 4D Path, Precede Biosciences; Other support (travel, accommodations, expenses): Roche/Genentech, Gilead Sciences, AstraZeneca, Daiichi Sankyo, Novartis, Merck. P. Lorusso: Financial Interests, Advisory Board: AbbVie, Takeda, Agenus, IQVIA, Pfizer, GSK, QED Therapeutics, AstraZeneca, EMD Serono, Kyowa Kirin Pharmaceutical Development, Kineta, Inc., Zentalis Pharmaceuticals, Molecular Templates, ABL Bio, STCube Pharmaceuticals, I-Mab, Seagen, imCheck, Relay Therapeutics, Stemline, Compass BADX, Mekanistic, Mersana Therapeutics, BAKX Therapeutics, Scenic Biotech, Qualigen, NeuroTrials, Actuate Therapeutics, Atreca Development, Quanta Therapeutics, Schrodinger, Boehrigner Ingelheim; Financial Interests, Other, imCORE Alliance: Roche-Genentech; Financial Interests, Speaker, Consultant, Advisor: SOTIO, I-Mab, Roivant Sciences; Financial Interests, Other, IDMC: SOTIO; Financial Interests, Advisory Board, Data Safety Monitoring Board: Amgen CodeBreak 202. M. Lustberg: Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Gilead; Financial Interests, Personal, Invited Speaker: Loxo Lilly; Financial Interests, Personal, Other, consultant: Pfizer. S. Sammons: Financial Interests, Institutional, Research Funding: AstraZeneca, Eli Lilly, Relay, SEAGEN, Sermonix; Financial Interests, Speaker, Consultant, Advisor, consulting: Foundation Medicine, AstraZeneca, Daichii Sankyo, Eli Lilly, Pfizer, Incyclix, Relay, Gilead, Sermonix, Novartis. N. Lin: Financial Interests, Research Funding: Genentech (and Zion Pharmaceutical as part of GNE), Pfizer, Merck, Seattle Genetics (now Pfizer), Olema Pharmaceuticals, AstraZeneca; Financial Interests, Speaker, Consultant, Advisor, consulting: Puma, Seattle Genetics, Daiichi Sankyo, AstraZeneca, Olema Pharmaceuticals, Janssen, Blueprint Medicines, Stemline/Menarini, Artera Inc., Eisai; Financial Interests, Royalties: UpToDate; Financial Interests, Other, travel support: Olema Pharmaceuticals. D. Rimm: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Cell Signaling Technology, Cepheid, Danaher, Daiichi Sankyo, Merck, Monopteros, Nanostring, PAIGE.AI, Regeneron, Ventana; Financial Interests, Personal, Speaker, Consultant, Advisor, consultant: Halda Bio, Immunogen, Incendia, NextCure, Sanofi, Verily; Financial Interests, Personal and Institutional, Research Funding: Amgen, Cepheid, Navigate BioPharma, NextCure, Konica/Minolta, Akoya; Financial Interests, Personal, Royalties: Rarecyte. S.M. Tolaney: Financial Interests, Research Funding: Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Seattle Genetics, OncoPep; Financial Interests, Speaker, Consultant, Advisor: Novartis, Pfizer (Seagen), Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Gilead, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, Sumitovant Biopharma, Umoja Biopharma, Artios Pharma, Menarini/Stemline, Aadi Bio, Bayer, Incyte Corp, Jazz Pharmaceuticals, Natera, Tango Therapeutics, Systimmune, eFFECTOR, Hengrui USA, Cullinan Oncology, Circle Pharma, Arvinas; Financial Interests, Other, travel support: Eli Lilly, Sanofi, Gilead, Jazz Pharma. All other authors have declared no conflicts of interest.
Resources from the same session
375P - Results from the Danish Breast Cancer Group's (DBCG) NAME-trial: A direct comparison of oral navelbine given either classic or metronomic in metastatic breast cancer
Presenter: Anne Sofie Brems-Eskildsen
Session: Poster session 15
376P - Evaluating adherence to oral anticancer medications in metastatic and non-metastatic breast cancer patients
Presenter: Rana El-Shewy
Session: Poster session 15
377P - Phase II study of trifluridine/tipiracil in pre-treated patients with ER-positive, HER2-negative metastatic breast cancer: A Dutch BOOG (2019-01 TIBET) study
Presenter: Niels Guchelaar
Session: Poster session 15
378P - Updated data on real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab
Presenter: Duan Yang
Session: Poster session 15
379P - Safety and efficacy of trastuzumab deruxtecan and concomitant radiation therapy in patients with metastatic breast cancer: A multicentre international retrospective cohort study
Presenter: Luca Visani
Session: Poster session 15
381P - Treatment rechallenge after grade 1 trastuzumab-deruxtecan related interstitial lung disease: A real-world experience
Presenter: Kelsey Natsuhara
Session: Poster session 15
382P - Pyrotinib combined with metronomic oral etoposide (VP-16) in heavily pretreated HER2-positive metastatic breast cancer: A single-arm, phase II study
Presenter: Jiaxuan Liu
Session: Poster session 15
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.